Sonoma Pharmaceuticals (SNOA) Stock: Buy, Sell, or Hold?
SNOA - Sonoma Pharmaceuticals, Inc. Common Stock
$1.23
0.07 (6.03%)
▲
5d:
-0.81%
30d:
-6.11%
90d:
-2.38%
HOLD
LOW Confidence
Analysis Updated: Oct 9, 2026 12:00 AM ET
Earnings: Nov 03, 2026
23d
Get Alerted When SNOA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SNOA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SNOA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SNOA is currently trading at $1.23, which is considered slightly low relative to its 30-day fair value range of $1.23 to $1.30.
Technical Outlook: Technically, SNOA is in a uptrend. Immediate support is located at $1.14, while resistance sits at $1.31. The stock is showing strong short-term momentum, up 6.0% recently.
Market Sentiment: SNOA scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $12.00 (+875.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SNOA is in a uptrend. Immediate support is located at $1.14, while resistance sits at $1.31. The stock is showing strong short-term momentum, up 6.0% recently.
Market Sentiment: SNOA scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $12.00 (+875.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.23 -
$1.30
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (61/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.0%)
- BULLISH: Trading 875.6% below Wall St target ($12.00)
- CAUTION: Bottoming setup, but lagging the sector by 12% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$1.23 -
$1.30
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.14
Resistance Level
$1.31
Current Trend
Uptrend
Technical data as of
Oct 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.20
Wall Street Target
$12.00
(+875.6%)
Revenue Growth (YoY)
59.6%
Profit Margin
-10.3%
Share & Embed Analysis
Last updated: October 10, 2026 8:22 AM ET
Data refreshes hourly during market hours. Next update: 9:22 AM
Data refreshes hourly during market hours. Next update: 9:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNOA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
28 analysts |
$208 | 54 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$57 | 62 BUY |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 58 HOLD |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$42 | 57 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 58 HOLD |
